Opioid Postmarketing Studies Could Quantify “Doctor Shopping”
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will hold two-day public meeting to get stakeholder input on how to design and conduct studies on serious risks of extended-release/long-acting opioids.